Potential End Point Adjudication (PEPA) Committee

The Potential End Point Adjudication committee (see WP schema) consists of site Principle Investigators, at least 3 other physicians who are knowledgeable in geriatric pharmacotherapy and who are approved by the Scientific Advisory Board. Potential endpoints will be identified by the site researcher in accordance with standardized protocol in which they will have received extensive training prior to the start of the trial. The relevant event details will be abstracted on a dedicated electronic Case Report Form. The committee will adjudicate the potential drug-related causality of the event and its severity using standardized criteria.